Chanazine 10%

4.1 Target species Horses. 4.2 Indications for use,specifying the target species Xylazine is a sedative with analgesic and muscle relaxant properties. The product is for use in horses only, in cases where sedation is required including: 1. Handling fractious animals e.g. for transportation. 2. Medical examinations e.g. X-ray examinations, removal of bandages; examination of the penis and oral cavity. 3. Premedication for minor superficial operations, and local or regional anaesthesia. 4. Elimination of defaecation when examining and treating the vagina, uterus and hindquarters. 4.3 Contraindications Do not administer by the intra-carotid route. Careful consideration should be given before administering to animals exposed to stress conditions such as extreme heat, cold, high altitude or fatigue. 4.4 Special warnings for each target species None known 4.5 Special precautions for use i. Special precautions for use in animals Should be used with caution when pulmonary disease is suspected. Do not exceed the recommended dosage ii. Special precautions to be taken by the person administering the veterinary medicinal product to animals Horses sedated with xylazine usually remain standing and may still kick with accuracy. Precaution should be taken to avoid accidental injection / self-injection. 1. In the case of accidental oral intake or self-injection, seek medical advice immediately and show the package leaflet to the doctor but DO NOT DRIVE as sedation and changes in blood pressure may occur. 2. Avoid skin, eye or mucosal contact. 3. Immediately after exposure, wash the exposed skin with large amounts of fresh water. 4. Remove contaminated clothes that are in direct contact with skin. 5. In the case of accidental contact of the product with eyes, rinse with large amounts of fresh water. If symptoms occur, seek the advice of a doctor. 6. If pregnant women handle the product, special caution should be observed not to self inject as uterine contractions and decreased foetal blood pressure may occur after accidental systemic exposure. 7. Advice to Doctors: Xylazine is an alpha2-adrenoreceptor agonist. Symptoms after absorption may involve clinical effects including dose-dependent sedation, respiratory depression, brachycardia, hypotension, a dry mouth, and hyperglycaemia. Ventricular arrhythmias have also been reported. Respiratory and haemodynamic symptoms should be treated symptomatically. 4.6 Adverse reactions (frequency and seriousness) Side effects of bradycardia, cardiac arrhythmia and polyuria may occur. Following intravenous administration a transient rise followed by a fall in blood pressure usually occurs. 4.7 Use during pregnancy, lactation or lay Xylazine should not be administered during the later stages of pregnancy because of the risk of inducing premature parturition. As the safety of xylazine use during organogenesis has not been fully demonstrated by current methods it should be used with caution during the first month of pregnancy. 4.8 Interaction with other medicinal products and other forms of interaction None known.
Vat Rate: 20%